Journal
BLOOD
Volume 125, Issue 24, Pages 3688-3693Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2015-01-567842
Keywords
-
Categories
Funding
- National Institutes of Health/National Cancer Institute [R01CA137060, R01CA139032, R01CA157644, R01CA169458, R01CA172558]
- William Lawrence and Blanche Hughes Foundation
- California Institute for Regenerative Medicine (CIRM) [TR2-01816]
- Leukaemia and Lymphoma Research
- Cancer Research UK
- Cancer Research UK [18131] Funding Source: researchfish
Ask authors/readers for more resources
Inhibitors of B-cell receptor (BCR) and pre-BCR signaling were successfully introduced into patient care for various subtypes of mature B-cell lymphoma (eg, ibrutinib, idelalisib). Acute lymphoblastic leukemia (ALL) typically originates from pre-B cells that critically depend on survival signals emanating from a functional pre-BCR. However, whether patients with ALL benefit from treatment with (pre-) BCR inhibitors has not been explored. Recent data suggest that the pre-BCR functions as tumor suppressor in the majority of cases of human ALL. However, a distinct subset of human ALL is selectively sensitive to pre-BCR antagonists.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available